



medicines  
patent  
pool



# Working to increase access to COVID-19 technologies in LMIC

## Contribution of the Medicines Patent Pool

Marie-Paule Kieny

1. The Medicines Patent Pool
  2. Access to Patented COVID-19 Treatments
  3. The mRNA Technology Transfer Hub
  4. MPP Tools to Monitor Patent Status of COVID-19 products
-

# THE MEDICINES PATENT POOL

MPP is a public health organization established in 2010 to accelerate **access to new HIV medicines** in LMICs

...and to facilitate the **development of new formulations needed in developing countries**


Operates through **voluntary licences** to facilitate early entry of **generic manufacturers** in LMICs

Expanded to work on **hepatitis C, Tuberculosis** (2016), other **patented essential medicines** (2018)...and **COVID-19** (2020)



The MPP is funded by:






## Guiding Principles


- |                        |                                |             |
|------------------------|--------------------------------|-------------|
| ✓ Public health driven | ✓ Focus on accelerating access | ✓ Flexible  |
| ✓ Transparent          | ✓ Complementary                | ✓ Voluntary |
|                        | ✓ Non-exclusive                |             |

## Molnupiravir Licence Territory

- Licences allow MPP to grant sub-licences
- Include confidential know-how
- Royalty-free during the WHO PHEIC
- Licensees can supply 105 or 95 countries respectively (approx. 4.1 billion people covered)
- Supply possible outside the territory if no patent infringement, including when a country issues a compulsory licence
- Require approval by WHO PQ or emergency use authorization
- Licences are fully transparent, available on MPP website



## Nirmatrelvir Licence Territory



## Licence on serological test with CSIC via WHO C-TAP

- Licence allows MPP to grant sub-licences to manufacturers anywhere in the world
- Licence includes **patents**, **biological material** and **know-how** necessary for manufacture of the diagnostic test
- Can be used to develop ELISA kits and lateral flow test for the detection of antibodies against COVID-19
- The territory is **worldwide**
- Royalty-free for LMICs; 15% for HICs
- Licence fully **transparent** on MPP website





NEWS & PRESS RELEASES » PRESS RELEASES

**WHO and MPP announce the first transparent, global, non-exclusive licence for a COVID-19 technology**

23 November 2021

# The mRNA Technology Transfer Hub



**South African consortium set up to build tech transfer hub & spokes network with local/regional partners**

## Intellectual Property Considerations for the Hub

- Underlying patents on mRNA technology have not been filed/granted in SA (nor in other countries where spokes will be operating)
- Patents have been identified in South Africa on specific COVID-19 vaccines (by Moderna)
- If Moderna's patented technologies are needed, Hub will rely on the research exception or commitment by Moderna not to enforce its patents on COVID-19 vaccines during pandemic and to licence after the pandemic ends
- If any other patents are identified on technology to be used by the Hub, MPP will seek licences from patent holders

MPP has developed two **free tools** containing information on:

- the patent status of essential medicines - including COVID-19 treatments - in LMICs called **MedsPaL**
- the patent status of COVID-19 vaccines worldwide called **VaxPaL**

**MedsPaL**  
THE MEDICINES PATENTS AND LICENCES DATABASE

[www.medspal.org](http://www.medspal.org)

**VaxPaL**  
COVID-19 VACCINES PATENT DATABASE

[www.vaxpal.org](http://www.vaxpal.org)